FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1858903318> ?p ?o ?g. }

• W1858903318 endingPage "343" @default.
• W1858903318 startingPage "337" @default.
• W1858903318 abstract "Purpose To report, from a retrospective analysis of prospectively collected data, on the feasibility, outcome, toxicity, and voice-handicap index (VHI) of patients with T1a glottic cancer treated by a novel intensity modulated radiation therapy technique developed at our institution to treat only the involved vocal cord: single vocal cord irradiation (SVCI). Methods and Materials Thirty patients with T1a glottic cancer were treated by means of SVCI. Dose prescription was set to 16 × 3.63 Gy (total dose 58.08 Gy). The clinical target volume was the entire vocal cord. Setup verification was done by means of an online correction protocol using cone beam computed tomography. Data for voice quality assessment were collected prospectively at baseline, end of treatment, and 4, 6, and 12 weeks and 6, 12, and 18 months after treatment using VHI questionnaires. Results After a median follow-up of 30 months (range, 7-50 months), the 2-year local control and overall survival rates were 100% and 90% because no single local recurrence was reported and 3 patients died because of comorbidity. All patients have completed the intended treatment schedule; no treatment interruptions and no grade 3 acute toxicity were reported. Grade 2 acute dermatitis or dysphagia was reported in only 5 patients (17%). No serious late toxicity was reported; only 1 patient developed temporary grade 2 laryngeal edema, and responded to a short-course of corticosteroid. The VHI improved significantly, from 33.5 at baseline to 9.5 and 10 at 6 weeks and 18 months, respectively (P<.001). The control group, treated to the whole larynx, had comparable local control rates (92.2% vs 100%, P=.24) but more acute toxicity (66% vs 17%, P<.0001) and higher VHI scores (23.8 and 16.7 at 6 weeks and 18 months, respectively, P<.0001). Conclusion Single vocal cord irradiation is feasible and resulted in maximal local control rate at 2 years. The deterioration in VHI scores was slight and temporary and subsequently improved to normal levels. Long-term follow-up is needed to consolidate these promising results. To report, from a retrospective analysis of prospectively collected data, on the feasibility, outcome, toxicity, and voice-handicap index (VHI) of patients with T1a glottic cancer treated by a novel intensity modulated radiation therapy technique developed at our institution to treat only the involved vocal cord: single vocal cord irradiation (SVCI). Thirty patients with T1a glottic cancer were treated by means of SVCI. Dose prescription was set to 16 × 3.63 Gy (total dose 58.08 Gy). The clinical target volume was the entire vocal cord. Setup verification was done by means of an online correction protocol using cone beam computed tomography. Data for voice quality assessment were collected prospectively at baseline, end of treatment, and 4, 6, and 12 weeks and 6, 12, and 18 months after treatment using VHI questionnaires. After a median follow-up of 30 months (range, 7-50 months), the 2-year local control and overall survival rates were 100% and 90% because no single local recurrence was reported and 3 patients died because of comorbidity. All patients have completed the intended treatment schedule; no treatment interruptions and no grade 3 acute toxicity were reported. Grade 2 acute dermatitis or dysphagia was reported in only 5 patients (17%). No serious late toxicity was reported; only 1 patient developed temporary grade 2 laryngeal edema, and responded to a short-course of corticosteroid. The VHI improved significantly, from 33.5 at baseline to 9.5 and 10 at 6 weeks and 18 months, respectively (P<.001). The control group, treated to the whole larynx, had comparable local control rates (92.2% vs 100%, P=.24) but more acute toxicity (66% vs 17%, P<.0001) and higher VHI scores (23.8 and 16.7 at 6 weeks and 18 months, respectively, P<.0001). Single vocal cord irradiation is feasible and resulted in maximal local control rate at 2 years. The deterioration in VHI scores was slight and temporary and subsequently improved to normal levels. Long-term follow-up is needed to consolidate these promising results." @default.
• W1858903318 created "2016-06-24" @default.
• W1858903318 creator A5003720242 @default.
• W1858903318 creator A5029187735 @default.
• W1858903318 creator A5050295879 @default.
• W1858903318 creator A5060080383 @default.
• W1858903318 creator A5061905561 @default.
• W1858903318 creator A5075628089 @default.
• W1858903318 creator A5080633542 @default.
• W1858903318 creator A5082719494 @default.
• W1858903318 creator A5089409373 @default.
• W1858903318 creator A5090717912 @default.
• W1858903318 date "2015-10-01" @default.
• W1858903318 modified "2023-10-16" @default.
• W1858903318 title "Single Vocal Cord Irradiation: Image Guided Intensity Modulated Hypofractionated Radiation Therapy for T1a Glottic Cancer: Early Clinical Results" @default.
• W1858903318 cites W1867472930 @default.
• W1858903318 cites W1981989535 @default.
• W1858903318 cites W1988026075 @default.
• W1858903318 cites W1992788772 @default.
• W1858903318 cites W2008439503 @default.
• W1858903318 cites W2016071787 @default.
• W1858903318 cites W2024575583 @default.
• W1858903318 cites W2036761012 @default.
• W1858903318 cites W2052914747 @default.
• W1858903318 cites W2067442869 @default.
• W1858903318 cites W2068933893 @default.
• W1858903318 cites W2077896357 @default.
• W1858903318 cites W2084349461 @default.
• W1858903318 cites W2113210661 @default.
• W1858903318 cites W2113919128 @default.
• W1858903318 cites W2116178479 @default.
• W1858903318 cites W2117609327 @default.
• W1858903318 cites W2120046399 @default.
• W1858903318 cites W2152481243 @default.
• W1858903318 cites W2159160276 @default.
• W1858903318 cites W2159239821 @default.
• W1858903318 cites W2161784001 @default.
• W1858903318 cites W2973515423 @default.
• W1858903318 doi "https://doi.org/10.1016/j.ijrobp.2015.06.016" @default.
• W1858903318 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26264629" @default.
• W1858903318 hasPublicationYear "2015" @default.
• W1858903318 type Work @default.
• W1858903318 sameAs 1858903318 @default.
• W1858903318 citedByCount "46" @default.
• W1858903318 countsByYear W18589033182016 @default.
• W1858903318 countsByYear W18589033182017 @default.
• W1858903318 countsByYear W18589033182018 @default.
• W1858903318 countsByYear W18589033182019 @default.
• W1858903318 countsByYear W18589033182020 @default.
• W1858903318 countsByYear W18589033182021 @default.
• W1858903318 countsByYear W18589033182022 @default.
• W1858903318 countsByYear W18589033182023 @default.
• W1858903318 crossrefType "journal-article" @default.
• W1858903318 hasAuthorship W1858903318A5003720242 @default.
• W1858903318 hasAuthorship W1858903318A5029187735 @default.
• W1858903318 hasAuthorship W1858903318A5050295879 @default.
• W1858903318 hasAuthorship W1858903318A5060080383 @default.
• W1858903318 hasAuthorship W1858903318A5061905561 @default.
• W1858903318 hasAuthorship W1858903318A5075628089 @default.
• W1858903318 hasAuthorship W1858903318A5080633542 @default.
• W1858903318 hasAuthorship W1858903318A5082719494 @default.
• W1858903318 hasAuthorship W1858903318A5089409373 @default.
• W1858903318 hasAuthorship W1858903318A5090717912 @default.
• W1858903318 hasConcept C121608353 @default.
• W1858903318 hasConcept C126322002 @default.
• W1858903318 hasConcept C126838900 @default.
• W1858903318 hasConcept C141071460 @default.
• W1858903318 hasConcept C167135981 @default.
• W1858903318 hasConcept C2779632786 @default.
• W1858903318 hasConcept C2780596822 @default.
• W1858903318 hasConcept C29730261 @default.
• W1858903318 hasConcept C509974204 @default.
• W1858903318 hasConcept C71924100 @default.
• W1858903318 hasConceptScore W1858903318C121608353 @default.
• W1858903318 hasConceptScore W1858903318C126322002 @default.
• W1858903318 hasConceptScore W1858903318C126838900 @default.
• W1858903318 hasConceptScore W1858903318C141071460 @default.
• W1858903318 hasConceptScore W1858903318C167135981 @default.
• W1858903318 hasConceptScore W1858903318C2779632786 @default.
• W1858903318 hasConceptScore W1858903318C2780596822 @default.
• W1858903318 hasConceptScore W1858903318C29730261 @default.
• W1858903318 hasConceptScore W1858903318C509974204 @default.
• W1858903318 hasConceptScore W1858903318C71924100 @default.
• W1858903318 hasIssue "2" @default.
• W1858903318 hasLocation W18589033181 @default.
• W1858903318 hasLocation W18589033182 @default.
• W1858903318 hasOpenAccess W1858903318 @default.
• W1858903318 hasPrimaryLocation W18589033181 @default.
• W1858903318 hasRelatedWork W1992138464 @default.
• W1858903318 hasRelatedWork W1998848462 @default.
• W1858903318 hasRelatedWork W2164373547 @default.
• W1858903318 hasRelatedWork W2352348542 @default.
• W1858903318 hasRelatedWork W2383166333 @default.
• W1858903318 hasRelatedWork W2559941419 @default.
• W1858903318 hasRelatedWork W2774680161 @default.
• W1858903318 hasRelatedWork W2895036280 @default.
• W1858903318 hasRelatedWork W3082763462 @default.
• W1858903318 hasRelatedWork W2188213098 @default.

• next